402 related articles for article (PubMed ID: 34431983)
1. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
[TBL] [Abstract][Full Text] [Related]
2. Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-Antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis.
Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S; Hutton B; Thavorn K
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):297-308. PubMed ID: 34695599
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
[TBL] [Abstract][Full Text] [Related]
4. Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.
Bei W; Qian J; Zilu Q; Kai C; Ruili J; Feng H; Liuqing C
Int Immunopharmacol; 2023 Oct; 123():110577. PubMed ID: 37567010
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
6. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Staubach P; Alvaro-Lozano M; Sekerel BE; Maurer M; Ben-Shoshan M; Porter M; Hua E; Ji Y; Burciu A; Savelieva M; Severin T; Drollmann A; Bienczak A
Pediatr Allergy Immunol; 2023 Jul; 34(7):e13982. PubMed ID: 37492920
[TBL] [Abstract][Full Text] [Related]
7. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
[TBL] [Abstract][Full Text] [Related]
8. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
10. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
11. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
13. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
14. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
Abe N; Bohgaki M; Kasahara H
Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
19. Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Chuang KW; Hsu CY; Huang SW; Chang HC
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2382-2389.e3. PubMed ID: 37263348
[TBL] [Abstract][Full Text] [Related]
20. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
[Next] [New Search]